Editorial commentary: TAVR —Is there a path to an all-surgical-risk indication?

Transcatheter aortic valve replacement (TAVR) has now become the standard of care for the treatment of severe symptomatic aortic valve stenosis in patients who are thought to be at least high surgical risk, and is an approved approach for patients who are at intermediate risk [1 –3]. The result of the PARTNER 2 (Placement of AoRTic TraNscathetER Valve Trial) trial provided support to the use of TAVR for patients with intermediate surgical risk [4]. The results of the SURTAVI trial led to the Food and Drug Administration (FDA) approval of the self-expandable valve for use in intermediate-risk category in the United States [5].

Source: Trends in Cardiovascular Medicine - August 28, 2017 Category: Cardiology Authors: Sameer Arora, John P. Vavalle Source Type: research